快而精醫藥 QGEN 深 滬
等待開盤 04-02 09:30:00 美东时间
40.38
+0.340
+0.85%
華盛通- 最 高40.63
- 今 開40.27
- 成交量 112.67万股
- 最 低 40.19
- 昨 收 40.04
- 總市值 83.21亿
- 52周最高 57.815
- 市盈率 靜 19.76
- 換手率 0.55%
- 52周最低 38.795
- 委 比 -63.66%
- 總股本 2.06亿
- 歷史最高 60.3887
- 量 比 0.76
- 振 幅 1.10%
- 歷史最低 7.7822
- 每 手 1
- 風險率 3.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
This Nio Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a comple...
03-13 19:45
Deutsche Bank Upgrades Qiagen to Buy, Maintains Price Target to $54
Deutsche Bank analyst Jan Koch upgrades Qiagen (NYSE:QGEN) from Hold to Buy and maintains the price target from $54 to $54.
03-13 18:32
Qiagen Obtains U.S. FDA Clearance For Gastrointestinal Panels On Fully Automated QIAstat-Dx Rise Syndromic Testing System
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the QIAstat-Dx Rise
03-11 05:11
快而精医药股价近期下跌2.17%，表现弱于大盘
经济观察网 快而精医药（QGEN.N）在近一周股价呈现波动下行态势，区间累计下跌2.17%，振幅达4.22%。截至2月23日收盘，股价报47.70美元，单日下跌...
02-24 03:53
HIVE Digital Technologies, First Majestic Silver, Iamgold And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling...
02-17 21:03
快而精医药获多家机构评级更新，股价近期表现稳健
经济观察网 近期多家华尔街机构更新了对快而精医药（QGEN.N）的评级与目标价。2026年2月6日，摩根大通维持“买入”评级，目标价60美元；花旗维持“持有”评...
02-14 00:42
美股大行评级 | 遭多家大行下调目标价！亚马逊、Affirm、Roblox、汤森路透、Doximity、OneMain、Atlassian、Peloton等等
今日重点评级关注：HC Wainwright & Co.：维持NovaBridge Biosciences"买入"评级，目标价从7美元升至9美元；Truist Securities：维持Reddit"买入"评级，目标价从270美元升至275美元
02-09 14:37
Stifel Maintains Hold on Qiagen, Raises Price Target to $50
Stifel analyst Daniel Arias maintains Qiagen (NYSE:QGEN) with a Hold and raises the price target from $45 to $50.
02-07 01:10
Qiagen FY2026 expected to be more than $2.50 vs $2.66 Est; FY2026 Revenue expected to be more than $2.194B vs $2.214B Est
Qiagen (NYSE:QGEN) FY2026 expected to be more than $2.50 vs $2.66 Est. FY2026 Revenue expected to be more than $2.194B vs $2.214B Est
02-05 06:06
